New preclinical data for RhoVac

New findings support the use of RhoVac’s cancer vaccine in several...

Whilst waiting on the readout of the BRaVac phase IIb study, RhoVac continues to build its data package around the cancer vaccine candidate onilcamotide....
Cyxone focuses on the RA programme

Cyxone focuses on the RA programme

First North-listed Cyxone recently published its Q1 report, a period during which the company carried out a rights issue of 61 MSEK, and advanced...
Annexin Pharmaceuticals

Annexin´s CMO on patent strategy

Stockholm-based Annexin Pharmaceuticals has recently obtained FDA approval for the company's phase II study in RVO, a production patent in the US, and a...
Respiratorius to split into two companies

Focus on company split for Respiratorius during Q4

Lund-based Respiratorius is currently undergoing an extensive transformation where the company’s two development projects are being separated. That process set the tone for the...
Cominie

CombiGene’s new project manager on a broadened pipeline

In parallel with CombiGene’s continued development of drug candidate CG01 together with Spark Therapeutics, the company is investigating the terrain to in-license additional promising...
Promore Pharma leg wounds

Promore Pharma aims to accelerate healing of venous leg ulcers

Peptide company Promore Pharma is undeniably in an exciting phase with two drug candidates in the field of wound treatment currently in late clinical...
Maintained focus on the portfolio for Sprint Bioscience

Sprint Bioscience maintains focus on developing the portfolio

With the activities for 2022 in full swing, Sprint Bioscience publishes the report for the year’s first quarter where we can note a continued...
Han moving chess piece Emplicure

Emplicure’s co-founder on the company’s next step

Since it was founded in 2014, Emplicure has transformed from being a company with potential and ambitions of going public to today having one...
Unchanged sales for Invent Medic

Unchanged sales figures for Invent Medic in Q1

Invent Medic has started 2022 on the offence, with several new initiatives and focus on increasing sales of the two products in the Efemia...
Train steaming ahead to symbolise progress

Emplicure steams towards key milestones in Amp01 and Empli03

Emplicure’s report for the first quarter of 2022 puts the emphasis on the preparations for the pharmacokinetic study with the main project Empli03. The...